Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Antisense and RNAi Therapeutics Market: By Technology: RNA Interference, siRNA, miRNA, Antisense RNA; By Application: Oncology, Cardiovascular Diseases, Others; By Route of Administration; Regional Analysis; Historical Market and Forecast (2018-2028); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Antisense and RNAi Therapeutics Market Outlook
The global antisense and RNAi therapeutics market attained a value of USD 1.45 billion in 2020 and is expected to grow at a CAGR of 8.5% during the forecast period of 2023-2028 owing to companies that are developing molecules based on antisense technology.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Segmentation
Antisense and RNAi therapeutics make particular and highly effective gene silencing possible. Antisense technology offers a chance to manipulate the expression of gene and thus, it is regarded as an efficient therapy for targeting ribonucleic acids (RNA). It is widely used for oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, infectious diseases, and others.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Antisense and RNAi therapeutics industry can be further divided based on:
- Technology
- RNA interference
- SiRNA
- MiRNA
- Antisense RNA
- Route of Administration
- Pulmonary Delivery
- Intravenous Injections
- Intra-dermal Injections
- Intraperitoneal Injections
- Topical Delivery
The EMR report looks into the regional antisense and RNAi therapeutics markets like the North America, Latin America, Europe, Middle East and Africa, and Asia Pacific.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
The global antisense and RNAi therapeutics industry is being driven by intensive study of gene functioning for disease management, through the use of malfunctioning gene and controlling its gene expression. The market is further driven by various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global antisense and RNAi therapeutics industry, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- OliX Pharmaceuticals Inc.
- Sanofi S.A, SAN (EPA)
- GlaxoSmithKline, GSK (LON)
- Ionis Pharmaceuticals
- Benitec Biopharma Ltd
- Silence Therapeutics Plc
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s five forces.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report | Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Technology, Application, Route of Administration, Region |
| Breakup by Technology | RNA Interference, siRNA, miRNA, Antisense RNA |
| Breakup by Application | Oncology, Cardiovascular Diseases, Respiratory Disorders, Renal Diseases, Neurodegenerative Disorders, Genetic Disorders, Infectious Diseases, Others |
| Breakup by Route of Administration | Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Others |
| Breakup by Region | North America, Europe, Asia Pacific, Latin America, Middle East and Africa |
| Market Dynamics | SWOT, Porter's Five Forces, Key Indicators for Price and Demand |
| Competitive Landscape | Market Structure, Company Profiles- Company Overview, Product Portfolio, Demographic Reach and Achievements, Certifications |
| Companies Covered | OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceuticals, Benitec Biopharma Ltd, Silence Therapeutics Plc, Others. |
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Snapshot
6.1 Global
6.2 Regional
7 Industry Opportunities and Challenges
8 Global Antisense and RNAi Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Antisense and RNAi Therapeutics Historical Market (2018-2022)
8.3 Global Antisense and RNAi Therapeutics Market Forecast (2023-2028)
8.4 Global Antisense and RNAi Therapeutics Market by Technology
8.4.1 RNA Interference
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 siRNA
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 miRNA
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2018-2022)
8.4.3.3 Forecast Trend (2023-2028)
8.4.4 Antisense RNA
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2018-2022)
8.4.4.3 Forecast Trend (2023-2028)
8.5 Global Antisense and RNAi Therapeutics Market by Application
8.5.1 Oncology
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Cardiovascular Diseases
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Respiratory Disorders
8.5.3.1 Market Share
8.5.3.2 Historical Trend (2018-2022)
8.5.3.3 Forecast Trend (2023-2028)
8.5.4 Renal Diseases
8.5.4.1 Market Share
8.5.4.2 Historical Trend (2018-2022)
8.5.4.3 Forecast Trend (2023-2028)
8.5.5 Neurodegenerative Disorders
8.5.5.1 Market Share
8.5.5.2 Historical Trend (2018-2022)
8.5.5.3 Forecast Trend (2023-2028)
8.5.6 Genetic Disorders
8.5.6.1 Market Share
8.5.6.2 Historical Trend (2018-2022)
8.5.6.3 Forecast Trend (2023-2028)
8.5.7 Infectious Diseases
8.5.7.1 Market Share
8.5.7.2 Historical Trend (2018-2022)
8.5.7.3 Forecast Trend (2023-2028)
8.5.8 Others
8.6 Global Antisense and RNAi Therapeutics Market by Route of Administration
8.6.1 Pulmonary Delivery
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028)
8.6.2 Intravenous Injections
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.6.3 Intra-dermal Injections
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2018-2022)
8.6.3.3 Forecast Trend (2023-2028)
8.6.4 Intra-dermal Injections
8.6.4.1 Market Share
8.6.4.2 Historical Trend (2018-2022)
8.6.4.3 Forecast Trend (2023-2028)
8.6.5 Intraperitoneal Injections
8.6.5.1 Market Share
8.6.5.2 Historical Trend (2018-2022)
8.6.5.3 Forecast Trend (2023-2028)
8.6.6 Topical Delivery
8.6.6.1 Market Share
8.6.6.2 Historical Trend (2018-2022)
8.6.6.3 Forecast Trend (2023-2028)
8.6.7 Others
8.7 Global Antisense and RNAi Therapeutics Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2018-2022)
9.1.2 Forecast Trend (2023-2028)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2018-2022)
9.2.2 Forecast Trend (2023-2028)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2018-2022)
9.3.2 Forecast Trend (2023-2028)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2018-2022)
9.4.2 Forecast Trend (2023-2028)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2018-2022)
9.5.2 Forecast Trend (2023-2028)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Value Chain Analysis
12 Competitive Landscape
12.1 Market Structure
12.2 Company Profiles
12.2.1 OliX Pharmaceuticals, Inc.
12.2.1.1 Company Overview
12.2.1.2 Product Portfolio
12.2.1.3 Demographic Reach and Achievements
12.2.1.4 Certifications
12.2.2 Sanofi S.A. SAN (EPA)
12.2.2.1 Company Overview
12.2.2.2 Product Portfolio
12.2.2.3 Demographic Reach and Achievements
12.2.2.4 Certifications
12.2.3 GlaxoSmithKline Plc GSK (LON)
12.2.3.1 Company Overview
12.2.3.2 Product Portfolio
12.2.3.3 Demographic Reach and Achievements
12.2.3.4 Certifications
12.2.4 Ionis Pharmaceuticals, Inc.
12.2.4.1 Company Overview
12.2.4.2 Product Portfolio
12.2.4.3 Demographic Reach and Achievements
12.2.4.4 Certifications
12.2.5 Benitec Biopharma Inc.,
12.2.5.1 Company Overview
12.2.5.2 Product Portfolio
12.2.5.3 Demographic Reach and Achievements
12.2.5.4 Certifications
12.2.6 Silence Therapeutics Plc
12.2.6.1 Company Overview
12.2.6.2 Product Portfolio
12.2.6.3 Demographic Reach and Achievements
12.2.6.4 Certifications
12.2.7 Others
13 Industry Events and Developments
List of Key Figures and Tables
1. Global Antisense and RNAi Therapeutics Market: Key Industry Highlights, 2018 and 2028
2. Global Antisense and RNAi Therapeutics Historical Market: Breakup by Technology (USD Million), 2018-2022
3. Global Antisense and RNAi Therapeutics Market Forecast: Breakup by Technology (USD Million), 2023-2028
4. Global Antisense and RNAi Therapeutics Historical Market: Breakup by Application (USD Million), 2018-2022
5. Global Antisense and RNAi Therapeutics Market Forecast: Breakup by Application (USD Million), 2023-2028
6. Global Antisense and RNAi Therapeutics Historical Market: Breakup by Route of Administration (USD Million), 2018-2022
7. Global Antisense and RNAi Therapeutics Market Forecast: Breakup by Route of Administration (USD Million), 2023-2028
8. Global Antisense and RNAi Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2022
9. Global Antisense and RNAi Therapeutics Market Forecast: Breakup by Region (USD Million), 2023-2028
10. North America Antisense and RNAi Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
11. North America Antisense and RNAi Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
12. Europe Antisense and RNAi Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
13. Europe Antisense and RNAi Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Asia Pacific Antisense and RNAi Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
15. Asia Pacific Antisense and RNAi Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Latin America Antisense and RNAi Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
17. Latin America Antisense and RNAi Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Middle East and Africa Antisense and RNAi Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2022
19. Middle East and Africa Antisense and RNAi Therapeutics Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Global Antisense and RNAi Therapeutics Market Structure
Key Questions Answered in the Report
In 2020, the global antisense and RNAi therapeutics market attained a value of nearly USD 1.45 billion.
The market is projected to grow at a CAGR of 8.5% between 2023 and 2028.
The major industry drivers are intensive study of gene functioning for disease management, through the use of malfunctioning gene, and controlling its gene expression.
The key trends in the market are various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery.
What are the major regional markets of antisense and RNAi therapeutics, according to the EMR report?
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The technology types include RNA interference, siRNA, miRNA, and antisense RNA.
The application sectors include oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, and infectious diseases, among others.
The routes of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, and topical delivery, among others.
The major players in the industry are OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceutical, Benitec Biopharma Ltd, Silence Therapeutics Plc, Others.
Analyst Review
The global antisense and RNAi therapeutics market attained a value of USD 1.45 billion in 2020, driven by the intensive study of gene functioning for disease management, through the use of malfunctioning gene and controlling its gene expression. Aided by the various collaborations taking place between pharmaceutical companies and contract research organisations, working to enhance drug delivery, the market is expected to witness a further growth in the forecast period of 2023-2028, growing at a CAGR of 8.5%.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The technology types include RNA interference, siRNA, miRNA, and antisense RNA. The application sectors include oncology, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, and infectious diseases, among others. The routes of administration include pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, and topical delivery, among others. The major regional markets for antisense and RNAi therapeutics are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include OliX Pharmaceuticals Inc., Sanofi S.A, SAN (EPA), GlaxoSmithKline, GSK (LON), Ionis Pharmaceutical, Benitec Biopharma Ltd, Silence Therapeutics Plc, Others
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2799-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER